London, UK – 24 September 2014 - The Board of Cell Medica is pleased to announce the appointment of Andrea Ponti as a non-executive director. Former Co-Head of Global Healthcare Investment Banking at J.P. Morgan, Andrea will provide the Cell Medica Board with an exceptional understanding of the strategic and financial drivers for success in the healthcare industry.
Cell Medica is a cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of cancer and infectious diseases. With over 25 years of experience in advising the leading pharmaceutical and biotechnology companies across the globe and an extensive network of contacts, Andrea will play an important role in developing partnership and commercialization opportunities for the Company’s immunotherapy products.
Dr Thomas Hecht, Chairman of Cell Medica, said, “In view of his professional experience as an adviser to the most important players in the healthcare industry, Andrea will add significant capabilities to Cell Medica´s Board. Andrea understands what drives success in the biotech space and will help guide the Company’s strategy to build a leader in the emerging industry of cellular immunotherapy.”
Notes to Editors:
About Andrea Ponti
Andrea Ponti is currently Co-Founder and Managing Partner at GHO Capital Partners LLP. Previously, he was Co-Head of Global Healthcare Investment Banking and Vice Chairman of Investment Banking in Europe at J.P. Morgan. Mr. Ponti joined J.P. Morgan in 2008 from Goldman Sachs, where he was Partner, Managing Director and Head of European Healthcare, Consumer and Retail investment banking, having founded the European Healthcare group in 1996. Mr. Ponti has advised on a number of industry-transforming transactions.
About Cell Medica
Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of cellular immunotherapy products for the treatment of cancer and infectious diseases. The Company has recently opened a ground-breaking international Phase 2 clinical trial exploring the therapeutic benefit of a novel cancer immunotherapy product for the treatment of advanced NK/T cell lymphoma.
Cellular immunotherapy is a new form of medical treatment which is transforming the treatment of cancer in the years ahead. The Company is targeting a range of cancer applications including lymphoma, leukaemia and nasopharyngeal carcinoma. Cell Medica’s lead product for the treatment of infectious diseases, Cytovir CMV, is commercially available in the UK for the treatment of cytomegalovirus (CMV) infections in patients following a bone marrow transplant.
Additional information can be found on the Company’s website: www.cellmedica.co.uk
Issued for and on behalf of Cell Medica by Instinctif Partners.
Tim WatsonAssociate Partner